Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2024 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

GLEN ALLEN, Va., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
November 05, 2024 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
October 17, 2024 09:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment

GLEN ALLEN, Va., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
October 15, 2024 09:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery

GLEN ALLEN, Va., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
September 19, 2024 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GLEN ALLEN, Va., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
September 04, 2024 09:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GLEN ALLEN, Va., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
August 14, 2024 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
August 13, 2024 09:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

GLEN ALLEN, Va., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
August 07, 2024 09:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04 Topline results expected during the fourth quarter GLEN ALLEN, Va., Aug. 07, 2024 (GLOBE NEWSWIRE)...
July 31, 2024 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

GLEN ALLEN, Va., July 31, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...